FTSE MIB
34.741,34 +402,02 (+1,17%) Dow Jones
39.387,76 +331,36 (+0,85%) Nasdaq
16.346,26 +43,46 (+0,27%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
79,80 +0,54 (+0,68%) Bitcoin EUR
58.848,54 +2.184,29 (+3,85%)
Synlogic, Inc. (SYBX)
| Chiusura precedente | 1,8700 |
| Aperto | 1,8800 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 1,8206 - 1,8800 |
| Intervallo di 52 settimane | 0,2340 - 5,7080 |
| Volume | |
| Media Volume | 51.129 |
| Capitalizzazione | 21,278M |
| Beta (5 anni mensile) | 1,03 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -8,8100 |
| Prossima data utili | 10 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1,00 |
GlobeNewswireSynlogic Announces Closing of $21.0 Million Underwritten Public Offering
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the closing of its previously announced underwritten public offering. The offering consisted of 7,394,363 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase up to 7,394,36
- GlobeNewswire
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the pricing of an underwritten public offering of (i) 7,394,363 shares of common stock (or common stock equivalents in lieu thereof) and (ii) accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock. The combined e
- GlobeNewswire
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the publication of results from its Synpheny-1 Phase 2 study of its drug candidates, labafenogene marselecobac (SYNB1934) and SYNB1618 in patients with phenylketonuria (PKU) in the journal Nature Metabolism. The publication, entitled “Efficacy and Safet
